Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
康基醫療:2023年度報告
KANGJI MEDICAL To Go Ex-Dividend On May 29th, 2024 With 0.45193 HKD Dividend Per Share And 1.09125 HKD Special Dividend Per Share
March 21st - $KANGJI MEDICAL(09997.HK)$ is trading ex-dividend on May 29th, 2024. Shareholders of record on May 30th, 2024 will receive 0.45193 HKD dividend per share and 1.09125 HKD special divid
Kangji Medical Holdings' Profit Rises 5% in 2023
Kangji Medical Holdings' (HKG:9997) attributable profit increased 5.3% to 504 million yuan, or 0.4299 yuan per share, in 2023, from 478.7 million yuan, or 0.3963 yuan per share, in 2022, according to
Changes in Hong Kong stocks | Kangji Healthcare (09997) fell more than 5% in the morning, net profit for the whole year increased by 5.3%, and the company cancelled the merger of Weijing Healthcare
Kangji Healthcare (09997) opened high and went low in early trading, falling more than 5% in the morning. As of press release, it was down 4.99% to HK$7.05, with a turnover of HK$23.9852 million.
Kangji Healthcare (09997) announced its 2023 annual results. Profit attributable to shareholders was 504 million yuan, an increase of 5.3% over the previous year
Kangji Healthcare (09997) announced its annual results for the year ended December 31, 2023, with revenue of 926 million yuan (...
Kangji Healthcare (09997.HK) cancels merger with Weijing Healthcare
Gelonghui, March 20, 丨 Kangji Medical (09997.HK) announced that on March 20, 2024, Weijing Healthcare shareholders have approved several amendments to Weijing Healthcare's organizational rules and changes in the composition of the board of directors. According to the revised Articles of Association of Weizheng Healthcare, the number of directors that Kangji Hong Kong is authorized to appoint has been reduced from 4 to 3 of the 7 directors of Weijing Healthcare's board of directors. As a result, Kangji Hong Kong will no longer be able to appoint most of the board members of Weijing Healthcare and will lose control of Weijing Healthcare. After the change in the composition of the board of directors takes effect, Weijing Medical will no longer be a subsidiary of the company, and Weijing Medical's finances
Kangji Healthcare (09997) will pay a final dividend of $0.41 per share on July 18
Kangji Healthcare (09997) announced that the company will pay a final dividend per share on July 18, 2024...
KANGJI MEDICAL: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Kangji Healthcare (09997.HK) plans to hold a board meeting on March 20 to approve annual results
GLONGHUI March 4 | Kangji Healthcare (09997.HK) announced that the company will hold a board meeting on March 20, 2024 (Wednesday) to consider and approve the results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements and proposals for payment of a final dividend (if any).
KANGJI MEDICAL: NOTICE OF BOARD MEETING
Express News | Worry-free Media completes acquisition of Kangji Healthcare's subsidiary
Kangji Healthcare (09997) cancelled 1.971,000 repurchased shares on January 31
Kangji Healthcare (09997) issued an announcement to cancel a total of 1.971,000 shares and have been repurchased on January 31, 2024...
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
January 18 Repurchase Collection | Tencent Holdings, Meituan-W, etc. bought back one after another, of which Tencent Holdings spent HK$1.03 billion
According to documents disclosed by the Hong Kong Stock Exchange on January 19, $Tencent Holdings (00700.HK) $ and $Meituan-W (03690.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.64 million common shares on January 18, involving an amount of HK$1,003 billion. The repurchase price for each share ranged from HK$278.8 to HK$271.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 169 million shares, accounting for 1.765% of the number of shares issued when the ordinary resolution was passed. ② $Meituan-W (0
Kangji Healthcare (09997) spent approximately HK$824,400 to buy back 125,500 shares on January 18
According to the Zhitong Finance App, Kangji Healthcare (09997) announced that on January 18, 2024, it spent approximately HK$824,400 to repurchase 125,500 shares, with a repurchase price of HK$6.52-6.61 per share.
January 17 Repurchase Collection | Tencent Holdings, Meituan-W, etc. bought back one after another, of which Tencent Holdings spent HK$1,002 billion
According to documents disclosed by the Hong Kong Stock Exchange on January 18, $Tencent Holdings (00700.HK) $ and $Meituan-W (03690.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.65 million common shares on January 17, involving an amount of HK$1,002 billion. The repurchase price for each share ranged from HK$277.6 to HK$272.4. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 166 million shares, accounting for 1.727% of the number of shares issued when the ordinary resolution was passed. ② $Meituan-W (0
Kangji Healthcare (09997) spent about HK$961,200 to buy back 150,000 shares on January 17
According to the Zhitong Finance App, Kangji Healthcare (09997) announced that on January 17, 2024, it spent approximately HK$961,200 to repurchase 150,000 shares at a repurchase price of HK$6.37-6.43 per share.
January 16 repurchase collection | Tencent Holdings, Meituan-W, etc. have repurchased, of which Tencent Holdings spent HK$801 million
According to documents disclosed by the Hong Kong Stock Exchange on January 17, $Tencent Holdings (00700.HK) $ and $Meituan-W (03690.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 2.83 million common shares on January 16, involving an amount of HK$801 million. The repurchase price per share ranged from HK$288.4 to HK$280. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 162 million shares, accounting for 1.689% of the number of shares issued when the ordinary resolution was passed. ② $Meituan-W (0369
No Data